Compound class:
Synthetic organic
Comment: KSP-1007 is a bicyclic boronic acid β-lactamase inhibitor (BLI), with broad-spectrum activity against both serine and metallo-β-lactamases, discovered through a collaboration between the Kitasato Institute (Tokyo, Japan) and Sumitomo Pharma (Osaka, Japan) [1]. KSP-1007, in combination with meropenem, is under clinical development for the treatment of infections caused by carbapenem-resistant bacterial infections.
|
|
Bioactivity Comments |
KSP-1007 displays potent activity against all classes of β-lactamase enzymes, including class B (Kiapp in the range 31.6 nM to 1.21 μM) and the class D (OXA) enzymes of Acinetobacter baumannii (Kiapp of 0.621-5.78 nM) [1]. The same study found that KSP-1007 potentiates the in vitro and in vivo activity of meropenem against carbapenemase-producing Enterobacterales, A. baumannii, and Pseudomonas aeruginosa. |